Equity Field Notes from temporal sources

[DanWebzster]

NBRV will file an NDA for lemefulin in CABP in Q4/18

Cash runway thru Q1/20

Public float has been bloated to achieve that cash runway

Despite efficacy proven in two Ph3 studies, recent stock weakness has been attributed to safety concerns

Safety concerns focus on diarrhea found in 12% of treatment arm compared to 1% of control arm.

Lemefulin will mostly be prescribed for drug resistant cases of CABP, approximately 5% of the market